AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS
Authors: A. Serrano-Combarro, B. Atienza-Mateo, N. Del-Val, L. Ibarrola Paino, I. Casafont-Solé, R. Melero, A. Pérez Linaza, I. Serrano-García, S. Castañeda, R. Ortega Castro, J. Calvo Gutierrez, N. Mena-Vázquez, N. Vegas-Revenga, L. Domínguez Casas, C. Delgado-Beltran, C. Díez, T. Pérez Sandoval, M. Retuerto-Guerrero, L. Pérez Albaladejo, R. López-Sánchez, M. G. Mazano, A. Brandy-Garcia, P. López Viejo, G. Bonilla, O. Maiz, M. D. C. Carrasco Cubero, M. Garijo Bufort, M. Moreno, A. Urruticoechea-Arana, S. Ordoñez, C. González-Montagut Gómez, C. Peralta-Ginés, J. R. De Dios Jiménez de Aberásturi, M. C. Osorio, E. Cañadillas, F. Lozano Morillo, T. Vazquez Rodriguez, P. Carreira, J. M. Blanco, C. Fernández-Díaz, J. Loricera, I. Ferraz-Amaro, D. Ferrer, R. Blanco
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD <b>[1-2].</b> Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations <b>[3].</b> However, it has not been studied in RA-ILD. <h3>Objectives</h3> to compare the effectiveness of ABA in RA-ILD patients according to the route of administration (IV-ABA vs SC-ABA). <h3>Methods</h3> National multicenter study of RA-ILD patients on treatment with ABA. They were divided into 2 groups according to the route of administration: a) IV, and b) SC. We analyzed from baseline the following outcomes in both groups: <b>a</b>) forced vital capacity (FVC), <b>b</b>) diffusing capacity of the lungs for carbon monoxide (DLCO), <b>c</b>) chest high resolution computed tomography (HRCT), <b>d</b>) dyspnea (assessed with the modified Medical Research Council scale), <b>e</b>) arthritis activity (assessed with DAS28-ESR or described in clinical records), and <b>f</b>) sparing corticosteroids effect. <h3>Results</h3> We studied a total of 392 [SC-ABA/IV-AB; 288/91(available data)] patients. Baseline demographic and clinical characteristics are shown in <b>Table 1</b>. Patients were followed-up for a median [IQR] of 24 [10-48] months. FVC and DLCO remain stable during the first 24 months in both SC-ABA and IV-ABA <b>[Figure 1].</b> Dyspnea stabilized or improved in 85% of patients (89% of IV-ABA; 83% of SC-ABA). ABA was withdrawn in 80 patients: 60 (39%) in SC-ABA group and 20 (22%) in IV-ABA group. ILD worsening and articular inefficacy were the most common reasons of ABA discontinuation. <h3>Conclusion</h3> In RA-ILD, ABA seems equally effective and safe regardless of the route of administration IV or SC. <h3>References</h3> [1] Rheumatology (Oxford). 2020 Dec 1;59(12):3906-3916. [2] Rheumatology (Oxford). 2021 Dec 24;61(1):299-308. [3] Arthritis Rheum. 2011 Oct;63(10):2854-64. <b>Members of the Spanish Collaborative Group of Abatacept in RA-ILD patients:</b> Luis Arboleya-Rodríguez, Javier Narváez, Juan Carlos Fernández, Belén Miguel, Iván Cabezas, Andrea García Valle, Clara Aguilera Cros, S. Romero-Yuste, Ignacio Villa Blanco, Sabela Fernández Aguado, Raquel Almodóvar, C. Ojeda-García, C. Aguilera-Cros, B. García-Magallón, Antonio Juan Mas, M. J. Moreno-Ramos, A. Ruibal-Escribano, Rosa Expósito, José Antonio Bernal, Evelin C. Cervantes, S. Rodríguez-García, R. Castellanos-Moreira, Iván Castellví, Manuel Rodríguez, Eva Salgado, Enrique Raya, Pilar Morales, Lorena Expósito, Mª Noelia Álvarez, José Luis Andreu, E. F. Vicente-Rabaneda, A. M. López-Robles, M. López-Corbeto, C. Hidalgo-Calleja, J.C. Fernández-López, Alejandro Olivé, S. Rodríguez-Muguruza, Iñigo Hernández, N. Quillis-Marti, J.A. Bernal-Vidal, A. García-Aparicio, S. Castro-Oreiro, J. Fernández-Melón, P. Vela Casasempere, María C. Fito, M. Rodríguez-Gómez, D. Palma-Sánchez, L. Expósito-Pérez, José María Andreu. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Ana Serrano-Combarro: None declared, Belén Atienza-Mateo: None declared, N. Del-Val: None declared, Libe Ibarrola Paino: None declared, Ivette Casafont-Solé: None declared, Rafael Melero: None declared, Alba Pérez Linaza: None declared, Isabel Serrano-García: None declared, Santos Castañeda: None declared, Rafaela Ortega Castro: None declared, Jerusalem Calvo Gutierrez: None declared, Natalia Mena-Vázquez: None declared, Nuria Vegas-Revenga: None declared, Lucía Domínguez Casas: None declared, C. Delgado-Beltran: None declared, Carolina Díez: None declared, Trinidad Pérez Sandoval: None declared, M. Retuerto-Guerrero: None declared, Lorena Pérez Albaladejo: None declared, R. López-Sánchez: None declared, Mª Guadalupe Mazano: None declared, Anahy Brandy-Garcia: None declared, Patricia López Viejo: None declared, Gemma Bonilla: None declared, Olga Maiz: None declared, Maria del Carmen Carrasco Cubero: None declared, Marta Garijo Bufort: None declared, Mireia Moreno: None declared, ANA URRUTICOECHEA-ARANA: None declared, Sergi Ordoñez: None declared, C. González-Montagut Gómez: None declared, C. Peralta-Ginés: None declared, Juan Ramón De Dios Jiménez de Aberásturi: None declared, Maria Camila Osorio: None declared, Elena Cañadillas: None declared, Fernando Lozano Morillo: None declared, Tomas Vazquez Rodriguez: None declared, Patricia Carreira: None declared, J M Blanco: None declared, Carlos Fernández-Díaz: None declared, J. Loricera: None declared, Iván Ferraz-Amaro: None declared, Diego Ferrer: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen, Galapagos and MSD, Consultant of: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD, novartis and Roche.